Noopept
- Category
- Brain & Cognition
- Administration routes
- Oral
- Regulatory status
- Not FDA-approved
What it is
Noopept is a synthetic dipeptide sold as a nootropic for memory and focus, active at doses roughly 1000 times lower than piracetam. Evidence for cognitive benefit is moderate, but neuroprotection, BDNF upregulation, and mood effects rest mainly on animal and mechanism studies, not confirmed human trials. Safety data beyond about 56 days does not exist. It is not an FDA-approved drug and is sold mainly as an unregulated research-grade or supplement product.
Read Full recordStudied uses & evidence
Studied uses(5)
Cognitive enhancement at very low doses (~1000x more potent than piracetam)
MediumConfirmed in animal studies; human evidence limited to small, unblinded Russian clinical trials.
Neuroprotection against amyloid-beta toxicity in Alzheimer's disease models
LowRodent and neuronal cell studies show protection against beta-amyloid toxicity; no human Alzheimer's trials yet.
Upregulation of BDNF and NGF in hippocampus and cortex (chronic treatment)
LowRat data show increased hippocampal NGF and BDNF expression and a smaller cortical BDNF increase after chronic treatment; this study did not assess human biomarkers.
Evidence limits
- Evidence Level
- Limited Clinical / Strong Preclinical
Clinical evidence for noopept includes several small studies. Among them is an open-label comparison (n=53) in patients with mild cognitive disorders, which showed improvements in cognition, mood, and anxiety with 56 days of treatment at 10mg BID. No placebo-controlled, double-blind trials have been published in English-language journals. Preclinical evidence is more extensive, with neuroprotective effects demonstrated in AD, ischemia, and excitotoxicity models. Almost all published studies originate from Russian laboratories at the Zakusov Institute. Noopept is registered as a nonprescription medicine in Russia.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(4)
Risks = level of concern: High · Moderate · Low · Theoretical
Unknown long-term safety (limited data beyond 56 days)
ModerateSleep disturbances (insomnia, vivid dreams)
LowIncreased blood pressure
TheoreticalIrritability and agitation
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.